[Nirmatrelvir/ritonavir (Paxlovid®), a treatment for Covid-19].

Buxeraud, Jacques; Faure, Sébastien; Fougere, Édouard

[Nirmatrelvir/ritonavir (Paxlovid®), a treatment for Covid-19]. / Le nirmatrelvir-ritonavir (Paxlovid®), un traitement contre la Covid-19.

Buxeraud, Jacques; Faure, Sébastien; Fougere, Édouard.

Afiliación

Buxeraud J; Faculté de pharmacie, 2 rue du Docteur-Marcland, 87025 Limoges cedex, France.
Faure S; Département Pharmacie, Faculté de santé, université d'Angers, 16 boulevard Daviers, 49045 Angers, France.
Fougere É; 68 rue du Cherche-Midi, 75006 Paris, France.

Actual Pharm ; 61(617): 10-12, 2022 Jun.

Article en Fr | MEDLINE | ID: mdl-35891982

ABSTRACT

ABSTRACT

The nirmatrelvir-ritonavir (Paxlovid®) is a treatment against Covid-19 available in pharmacies since February 4, 2022. Administered orally, it is intended only for people at very high risk of contracting one or more severe forms of the disease.

Palabras clave

Covid-19; antiviral; nirmatrelvir; ritonavir

Texto completo

Imprimir

XML

PubMed Links

Buscar en Google

Texto completo: 1 Bases de datos: MEDLINE Idioma: Fr Revista: Actual Pharm Año: 2022 Tipo del documento: Article País de afiliación: Francia

Texto completo

Imprimir

XML

PubMed Links

Buscar en Google

Texto completo: 1 Bases de datos: MEDLINE Idioma: Fr Revista: Actual Pharm Año: 2022 Tipo del documento: Article País de afiliación: Francia